GSK eyes life after a patent cliff
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline is shifting "from being a blockbuster-dependent" company that relies on a single patented drug for a bulk of its revenue to a "blockbuster-ready" firm with a well-diversified portfolio that provides protection if the next big drug comes too late to offset generic competition for the current top-seller, CEO Andrew Witty says. At Cowen & Co.'s Health Care Conference March 17 in Boston, Witty said GSK is seeking diversity rather than the next blockbuster drug to "diminish the possibility of simply going back to another patent cliff," like the one it fell off last year when it lost exclusivity for several prescription drugs. GSK will invest in multiple small prescription drugs and seeks bolt-on acquisitions of vaccines and brands in "the consumer emerging market" to reduce the impact of any one patent expiry, Witty said (1"The Tan Sheet" Feb. 9, 2009, p. 9)
You may also be interested in...
GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs
Philips CEO Roy Jakobs talks to Medtech Insight about the medtech firm’s decade-long history of embedding AI into its products and what he expects from the newly released draft framework by the National Academy of Medicine, which he helped develop as co-chair of the Steering Committee.
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.